In last trading session, Standard BioTools Inc (NASDAQ:LAB) saw 1.02 million shares changing hands with its beta currently measuring 1.56. Company’s recent per share price level of $1.39 trading at -$0.01 or -0.71% at ring of the bell on the day assigns it a market valuation of $517.44M. That closing price of LAB’s stock is at a discount of -118.71% from its 52-week high price of $3.04 and is indicating a premium of 15.83% from its 52-week low price of $1.17.
For Standard BioTools Inc (LAB), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.03 in the current quarter.
Standard BioTools Inc (NASDAQ:LAB) trade information
Upright in the red during last session for losing -0.71%, in the last five days LAB remained trading in the green while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $1.39 price level, adding 7.95% to its value on the day. Standard BioTools Inc’s shares saw a change of -20.57% in year-to-date performance and have moved 6.51% in past 5-day. Standard BioTools Inc (NASDAQ:LAB) showed a performance of -21.47% in past 30-days.
Wall Street analysts have assigned a consensus price target of 3.25 to the stock, which implies a rise of 57.23% to its current value. Analysts have been projecting 3.25 as a low price target for the stock while placing it at a high target of 3.25. It follows that stock’s current price would drop -133.81% in reaching the projected high whereas dropping to the targeted low would mean a loss of -133.81% for stock’s current value.
Standard BioTools Inc (LAB) estimates and forecasts
This year revenue growth is estimated to rise 60.99% from the last financial year’s standing.
3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 43.03M for the same. And 2 analysts are in estimates of company making revenue of 45.6M in the next quarter. Company posted 28.19M and 45.54M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 8.72% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 62.06% while estimates for its earnings growth in next 5 years are of 56.66%.
Standard BioTools Inc (NASDAQ:LAB)’s Major holders
CASDIN CAPITAL, LLC is the top institutional holder at LAB for having 63.96 million shares of worth $113.21 million. And as of 2024-06-30, it was holding 17.1782 of the company’s outstanding shares.
The second largest institutional holder is VIKING GLOBAL INVESTORS LP, which was holding about 58.65 million shares on 2024-06-30. The number of shares represents firm’s hold over 15.7524 of outstanding shares, having a total worth of $103.81 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 9.27 shares of worth $12.88 million or 2.49% of the total outstanding shares. The later fund manager was in possession of 8.21 shares on Nov 30, 2024 , making its stake of worth around $11.41 million in the company or a holder of 2.21% of company’s stock.
